Melanotan I: Molecular Characterization and Receptor Pharmacology — A Research Reference

Alpha-MSH is a thirteen-residue melanocortin peptide, acetylated at its amino terminus and amidated at its carboxyl terminus, carrying the four-residue histidine-phenylalanine-arginine-tryptophan motif that the melanocortin receptors engage.

Melanotan I retains all thirteen positions and both terminal modifications, changing two residues. At position 4, norleucine replaces methionine — an isosteric substitution that preserves side-chain size and hydrophobicity while removing the sulphur atom, and with it the most oxidation-prone residue in the natural sequence. At position 7, the phenylalanine of the core motif is inverted to the D configuration, which alters the local backbone geometry and removes a protease-labile stereocentre, since proteases act on L-amino acid sequences.

Both substitutions were introduced together, and the resulting compound established the design principle the field then followed: modify the residues that limit stability, leave the receptor-engaging motif chemically untouched [1]. Every analogue discussed in this catalogue's melanocortin pages descends from that result — including the cyclic compounds, whose disulfide-bridged predecessors were reported by the same group two years later [4].

The result is a linear peptide — no ring, no bridge — with a molecular weight of approximately 1,647 daltons.

The Receptor Family

The melanocortin receptors are five class A G-protein-coupled receptors, MC1R through MC5R, cloned as a family in the early 1990s — more than a decade after this compound was characterized, which is why the original pharmacology predates any receptor-subtype description [2]. They couple principally to Gαs; activation stimulates adenylyl cyclase and raises intracellular cyclic AMP.

A crystal structure of MC4R in its active state, bound to a peptide agonist and coupled to its G protein, later resolved the activation mechanism and the ligand-binding pocket architecture [3]. That work also identified a calcium ion participating directly in the agonist-binding site — an unusual feature among class A receptors, and one that makes buffer ionic composition a variable of the binding site rather than merely of the medium.

Position of this compound

Melanotan I is characterized as a non-selective agonist across the receptor family, engaging several subtypes rather than discriminating sharply among them — a property of the conserved core motif it retains in full. Its enduring role in receptor-pharmacology work is as a reference agonist: a linear, conformationally unconstrained compound of well-established potency against which constrained and subtype-selective analogues are compared.

The contrast with Melanotan II is instructive despite the shared name. That compound is a cyclic heptapeptide of roughly 1,024 daltons; this one is a linear tridecapeptide some six hundred daltons heavier. They share the core motif and little else structurally, and the numbering reflects sequence of development rather than any relationship of revision.

Mass spectrometry confirms the intact molecular mass near 1,647 daltons, and for this compound the theoretical figure encodes three features at once: the substituted sequence, the N-terminal acetyl group, and the C-terminal amide. A missing acetyl group lightens the molecule by a defined 42-dalton increment; a free acid in place of the amide shifts it by roughly one dalton. Both are defined deviations detectable at adequate resolving power.

The six-hundred-dalton separation from Melanotan II makes that particular identity question trivial here — a welcome contrast to the one-dalton problem elsewhere in this family.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. In a thirteen-residue synthesis the familiar related substances are deletion sequences, where a residue failed to couple. The substitution-specific one is the diastereomer: the D-phenylalanine at position 7 can invert to the L form during synthesis, producing a compound of identical mass that mass spectrometry cannot detect at all and that separates only chromatographically.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided.

The norleucine substitution removes methionine, and with it the most common oxidation route in the natural sequence — one of the two engineering decisions in the molecule working directly in storage's favour. Tryptophan remains at position 9 and is photosensitive, which is reason enough to keep solutions out of direct light; amber vials or foil wrapping during extended handling is standard practice for sequences containing it.

A thirteen-residue linear peptide sits in the middle of the size range: long enough to have real conformational flexibility once dissolved, short enough that the aggregation pressure affecting forty-residue chains is largely absent. It dissolves readily, and vigorous agitation is unnecessary.

Material supplied by HEEZ Research is research-grade and is not a pharmaceutical product. No manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade Melanotan I is accompanied by an independent certificate of analysis specific to that lot.

Melanotan I is a linear tridecapeptide of approximately 1,647 daltons — alpha-MSH carrying norleucine at position 4 and D-phenylalanine at position 7, with both terminal modifications of the parent retained. Reported in 1980 as substantially more potent and longer-acting in vitro than the natural hormone, it established the substitution strategy that the melanocortin field then followed and remains a reference agonist across the MC1R–MC5R family. Analytical verification rests on mass confirmation of the substituted, acetylated, amidated sequence and chromatographic resolution of deletion sequences and a mass-identical position-7 diastereomer.